Scarica l'app Stockscreener
13.26
1.77%
0.23
Dopo l'orario di chiusura:
13.26
Precedente Chiudi:
$13.03
Aprire:
$13.03
Volume 24 ore:
14,219
Relative Volume:
0.73
Capitalizzazione di mercato:
$91.71M
Reddito:
$56.54M
Utile/perdita netta:
$-30.70M
Rapporto P/E:
-34.00
EPS:
-0.39
Flusso di cassa netto:
$-31.05M
1 W Prestazione:
-0.97%
1M Prestazione:
+21.65%
6M Prestazione:
+6.00%
1 anno Prestazione:
-18.15%
Intervallo 1D:
$13.00
$13.26
Intervallo di 1 settimana:
$12.65
$13.45
Portata 52W:
$10.00
$24.40
Cidara Therapeutics Inc Stock (CDTX) Company Profile
Nome
Cidara Therapeutics Inc
Settore
Industria
Telefono
858-752-6170
Indirizzo
6310 NANCY RIDGE DRIVE, SAN DIEGO, CA
Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-14 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2021-12-03 | Ripresa | H.C. Wainwright | Buy |
| 2021-09-22 | Aggiornamento | WBB Securities | Buy → Strong Buy |
| 2021-03-04 | Iniziato | Aegis Capital | Buy |
| 2019-09-04 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2018-07-26 | Iniziato | Citigroup | Buy |
| 2017-04-21 | Iniziato | Raymond James | Strong Buy |
| 2017-04-17 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-12 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-04-11 | Ripresa | Wedbush | Outperform |
| 2017-02-22 | Reiterato | H.C. Wainwright | Buy |
| 2017-02-22 | Aggiornamento | WBB Securities | Sell → Hold |
| 2016-12-21 | Ripresa | Leerink Partners | Outperform |
| 2016-12-19 | Iniziato | H.C. Wainwright | Buy |
| 2016-09-23 | Downgrade | WBB Securities | Hold → Sell |
| 2015-10-09 | Aggiornamento | WBB Securities | Sell → Hold |
| 2015-05-11 | Iniziato | Jefferies | Buy |
| 2015-05-11 | Iniziato | Leerink Partners | Outperform |
| 2015-05-11 | Iniziato | Needham | Buy |
| 2015-05-11 | Iniziato | Wedbush | Outperform |
| 2015-04-23 | Iniziato | WBB Securities | Sell |
Mostra tutto
Cidara Therapeutics Inc Borsa (CDTX) Ultime notizie
Will Rezafungin Trial Data ReSTORE Investors' Faith In Cidara? - RTTNews
Cidara Therapeutics to Participate in Two Upcoming November Investor Conferences - GlobeNewswire
How Cidara Got Its Molecule Back - BioProcess Online
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Sees Significant Drop in Short Interest - MarketBeat
Cidara Therapeutics (NASDAQ:CDTX) Receives “Buy” Rating from HC Wainwright - Defense World
Cidara Therapeutics (NASDAQ:CDTX) Receives Buy Rating from HC Wainwright - MarketBeat
Cidara Therapeutics (NASDAQ:CDTX) Stock Price Passes Below Fifty Day Moving AverageWhat's Next? - MarketBeat
Cidara Therapeutics Announces Two Presentations on Drug-Fc Conjugate, CD388, at IDWeek 2024 - GlobeNewswire
(CDTX) Investment Analysis and Advice - Stock Traders Daily
Influenza Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Invasive Fungal Infection Market 2034 | Key Brands -Cidara Therapeutics, Basilea Pharmaceutica, Pfizer, GlaxoSmithKline, – IndiaPolitics.com - IndiaPolitics.com
(CDTX) On The My Stocks Page - Stock Traders Daily
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Marketscreener.com
Shattuck Labs stock craters following pipeline and job cuts - Pharmaceutical Technology
Cidara Therapeutics Announces Two Presentations on - GlobeNewswire
Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference - StockTitan
How to Take Advantage of moves in (CDTX) - Stock Traders Daily
Long-acting Antiviral for Pre-exposure Protection Against Influenza Launches Phase 2b Study - Precision Vaccinations
Cidara Therapeutics begins phase 2b trial for flu prophylaxis By Investing.com - Investing.com Australia
Adverum Biotechnologies (NASDAQ:ADVM) & CRISPR Therapeutics (NASDAQ:CRSP) Head to Head Comparison - Defense World
Cidara starts Phase 2b trial of influenza drug CD388 By Investing.com - Investing.com Canada
Codexis, Inc. (NASDAQ:CDXS) Major Shareholder Opaleye Management Inc. Purchases 45,000 Shares - Defense World
Cadence Design Systems Inc. stock rises Monday, still underperforms market - MarketWatch
Xponance Inc. Has $24.15 Million Holdings in Cadence Design Systems, Inc. (NASDAQ:CDNS) - Defense World
Cidara Therapeutics begins phase 2b trial for flu prophylaxis - Investing.com India
CTXR’s price-to-book ratio: An indicator of the company’s performance - US Post News
Cidara starts Phase 2b trial of influenza drug CD388 - Investing.com
Cidara Therapeutics Announces First Subjects Dosed in Phase - GlobeNewswire
Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza - StockTitan
Biotechs investigate ways to adapt to new clinical trial regulation and economic flux - Yahoo Finance
Cidara Therapeutics expands Scientific Advisory Board By Investing.com - Investing.com Canada
Cardlytics Inc [NASDAQ: CDLX] Sees Increase in Stock Value - Knox Daily
XTX Topco Ltd Purchases Shares of 8,284 Cadence Design Systems, Inc. (NASDAQ:CDNS) - Defense World
Cidara Therapeutics expands Scientific Advisory Board - Investing.com
Cidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts - GlobeNewswire
Acute Vulvovaginal Candidiasis Treatment Market Size, Share, Growth and Industry Trends - meramandsaur.in
Capricor sells Europe rights to DMD therapy for $35M as FDA application approaches - Fierce Biotech
IDWeek 2022 PresentationsIVVD, SPRO, INVA, CDTX, ANTX, GSK - RTTNews
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Sees Large Decrease in Short Interest - MarketBeat
Codexis Inc. (CDXS) Stock: A Year of Declines and Increases - The InvestChronicle
The time has not yet come to remove your chips from the table: Citius Pharmaceuticals Inc (CTXR) - SETE News
Capricor Therapeutics Shares Rise After Deramiocel Deal With Nippon Shinyaku - MarketWatch
Examining Citius Pharmaceuticals Inc (CTXR) stock is warranted - US Post News
HC Wainwright Reaffirms "Buy" Rating for Cidara Therapeutics (NASDAQ:CDTX) - MarketBeat
Cognizant Technology Solutions (NASDAQ:CTSH) Stock Rating Upgraded by StockNews.com - Defense World
Cidara therapeutics chief scientific officer sells shares worth over $10k - Investing.com India
Cidara Therapeutics (NASDAQ:CDTX) Upgraded to "Hold" at StockNews.com - MarketBeat
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Insider Sells $10,755.36 in Stock - MarketBeat
Cidara Therapeutics executive sells over $10k in company stock - Investing.com
(CDTX) Trading Advice - Stock Traders Daily
Cidara Therapeutics Inc Azioni (CDTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cidara Therapeutics Inc Azioni (CDTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Tari Leslie | CHIEF SCIENTIFIC OFFICER |
Sep 11 '24 |
Sale |
11.64 |
909 |
10,580 |
17,788 |
| Stein Jeffrey | President & CEO |
Jun 07 '24 |
Buy |
13.21 |
8,000 |
105,680 |
24,580 |
| Tari Leslie | CHIEF SCIENTIFIC OFFICER |
Mar 11 '24 |
Sale |
0.67 |
21,029 |
14,085 |
258,681 |
| Sandison Taylor | Chief Medical Officer |
Mar 11 '24 |
Sale |
0.67 |
20,662 |
13,839 |
347,095 |
| Ward Shane | COO & CLO |
Mar 11 '24 |
Sale |
0.67 |
20,473 |
13,713 |
198,770 |
| Shah Preetam | CFO & CBO |
Mar 11 '24 |
Sale |
0.67 |
18,931 |
12,680 |
227,210 |
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):